Beat C Bornhauser

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8565061/publications.pdf

Version: 2024-02-01

66	4,247	186265 28	133252 59
papers	citations	h-index	g-index

67	67	67	8960
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clonal dynamics in pediatric Bâ€cell precursor acute lymphoblastic leukemia with very early relapse. Pediatric Blood and Cancer, 2022, 69, e29361.	1.5	9
2	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. Leukemia, 2022, 36, 1759-1768.	7.2	4
3	<scp>LRH</scp>â€1/<scp>NR5A2</scp> interacts with the glucocorticoid receptor to regulate glucocorticoid resistance. EMBO Reports, 2022, 23, .	4.5	7
4	Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia. Haematologica, 2021, 106, 886-890.	3.5	9
5	DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. Journal of Clinical Investigation, 2021, 131, .	8.2	47
6	14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia. Blood, 2021, 138, 773-784.	1.4	19
7	MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia, 2021, 35, 3394-3405.	7.2	28
8	A Hopeful Leap Forward by Multicentric Cooperation for Precision-Based Therapy for Very Resistant, Relapsed, or Refractory Childhood Leukemia. Cancer Discovery, 2021, 11, 1322-1323.	9.4	1
9	BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. Blood, 2021, 138, 2383-2395.	1.4	13
10	Chemoresistance and Drug Profiling in ALL. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S57-S58.	0.4	2
11	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 342	9.1	1,430
12	High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. Cells, 2021, 10, 2853.	4.1	2
13	Single-cell analysis of structural variations and complex rearrangements with tri-channel processing. Nature Biotechnology, 2020, 38, 343-354.	17.5	59
14	TNFR2 is required for RIP1-dependent cell death in human leukemia. Blood Advances, 2020, 4, 4823-4833.	5.2	8
15	Chromatin accessibility landscape of pediatric Tâ€lymphoblastic leukemia and human Tâ€cell precursors. EMBO Molecular Medicine, 2020, 12, e12104.	6.9	13
16	Rapid Generation of Leukemogenic Chromosomal Translocations in Vivo Using CRISPR/Cas9. HemaSphere, 2020, 4, e456.	2.7	4
17	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Advances, 2020, 4, 4052-4064.	5.2	5
18	Pharmacological disruption of the Notch transcription factor complex. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16292-16301.	7.1	64

#	Article	IF	Citations
19	Repurposing anthelmintic agents to eradicate resistant leukemia. Blood Cancer Journal, 2020, 10, 72.	6.2	3
20	Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. Clinical Cancer Research, 2020, 26, 3307-3318.	7.0	28
21	The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL. Blood, 2020, 136, 20-20.	1.4	1
22	In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients. Blood, 2020, 136, 15-16.	1.4	0
23	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica, 2019, 104, e17-e20.	3.5	18
24	Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7. Science Advances, 2019, 5, eaau9433.	10.3	172
25	Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death and Disease, 2019, 10, 571.	6.3	29
26	The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. Cancer Cell, 2019, 36, 630-644.e9.	16.8	35
27	Î³-Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2019, 35, 649-663.e10.	16.8	20
28	Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia. Frontiers in Cell and Developmental Biology, 2019, 7, 40.	3.7	10
29	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. Blood Advances, 2019, 3, 3143-3156.	5.2	4
30	USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia. Clinical Cancer Research, 2019, 25, 222-239.	7.0	66
31	Inducible Phase Separation of GSK3Î± As a Mechanism for Asparaginase Resistance in Acute Leukemias. Blood, 2019, 134, 169-169.	1.4	0
32	IKZF1^{plus} Defines a New Minimal Residual Diseaseâ€“Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 1240-1249.	1.6	194
33	<scp>PDX</scp> models recapitulate the genetic and epigenetic landscape of pediatric Tâ€cell leukemia. EMBO Molecular Medicine, 2018, 10, .	6.9	38
34	Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 34, 271-285.e7.	16.8	48
35	Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes. Blood, 2018, 132, 1545-1545.	1.4	0
36	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood, 2017, 129, e26-e37.	1.4	195

#	Article	IF	Citations
37	CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies. Blood, 2017, 130, 297-309.	1.4	37
38	Clinical or ATPase domain mutations in ABCD4 disrupt the interaction between the vitamin B12-trafficking proteins ABCD4 and LMBD1. Journal of Biological Chemistry, 2017, 292, 11980-11991.	3.4	36
39	Efficient Generation of Multi-gene Knockout Cell Lines and Patient-derived Xenografts Using Multi-colored Lenti-CRISPR-Cas9. Bio-protocol, 2017, 7, e2222.	0.4	2
40	Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. Science Translational Medicine, 2016, 8, 339ra70.	12.4	92
41	Genomics and drug profiling of fatal TCF3-HLFâ˚positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nature Genetics, 2015, 47, 1020-1029.	21.4	190
42	Drug Response Profiling to Identify Selective Pharmacological Activity in Drug Resistant ALL. Blood, 2015, 126, 2532-2532.	1.4	0
43	Activation of Simultaneous Apoptosis and Necroptosis to Eradicate Drug Resistant Leukemia. Blood, 2015, 126, 1283-1283.	1.4	0
44	Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. Oncotarget, 2014, 5, 11501-11512.	1.8	37
45	Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts. Clinical Cancer Research, 2014, 20, 4520-4531.	7.0	67
46	The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica, 2014, 99, e188-e192.	3.5	114
47	Leukemia surfaceome analysis reveals new disease-associated features. Blood, 2013, 121, e149-e159.	1.4	63
48	Fibroblast Growth Factor-21 (FGF21) Regulates Low-density Lipoprotein Receptor (LDLR) Levels in Cells via the E3-ubiquitin Ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting Saposin-like Protein (Msap). Journal of Biological Chemistry, 2012, 287, 12602-12611.	3.4	56
49	CD133 Positive Embryonal Rhabdomyosarcoma Stem-Like Cell Population Is Enriched in Rhabdospheres. PLoS ONE, 2011, 6, e19506.	2.5	111
50	Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood, 2011, 118, 1854-1864.	1.4	73
51	Alternative technique for intrafemoral injection and bone marrow sampling in mouse transplant models. Leukemia and Lymphoma, 2011, 52, 1806-1808.	1.3	3
52	Tissue Expression and Actin Binding of a Novel N-Terminal Utrophin Isoform. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-18.	3.0	0
53	Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?. Expert Review of Hematology, 2010, 3, 369-372.	2.2	2
54	Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. Journal of Clinical Investigation, 2010, 120, 1310-1323.	8.2	287

#	Article	IF	Citations
55	Dexamethasone regulates expression of BRUCE/Apollon and the proliferation of neural progenitor cells. FEBS Letters, 2009, 583, 2213-2217.	2.8	15
56	Mylip makes an Idol turn into regulation of LDL receptor. Cellular and Molecular Life Sciences, 2009, 66, 3399-3402.	5.4	14
57	DOWN'S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation â€“ A REPORT FROM the Ibfm-STUDY GROUP.. Blood, 2009, 114, 11-11.	1.4	2
58	Leukemia-Initiating Cells Are Frequent in Very High Risk Childhood Acute Lymphoblastic Leukemia and Give Rise to Relatively Stable Phenotypes in Immunodeficient Mice.. Blood, 2009, 114, 86-86.	1.4	2
59	Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood, 2007, 110, 2084-2091.	1.4	53
60	PDGF regulates the actin cytoskeleton through hnRNP-K-mediated activation of the ubiquitin E3-ligase MIR. EMBO Journal, 2006, 25, 1871-1882.	7.8	21
61	Functional activities and cellular localization of the ezrin, radixin, moesin (ERM) and RING zinc finger domains in MIR. FEBS Letters, 2003, 553, 195-199.	2.8	20
62	MSAP Is a Novel MIR-interacting Protein That Enhances Neurite Outgrowth and Increases Myosin Regulatory Light Chain. Journal of Biological Chemistry, 2003, 278, 35412-35420.	3.4	54
63	Identification and characterisation of transcript and protein of a new short N-terminal utrophin isoform. , 2000, 77, 418-431.		20
64	Differential expression of utrophin and dystrophin in CNS neurons: An in situ hybridization and immunohistochemical study. Journal of Comparative Neurology, 2000, 422, 594-611.	1.6	62
65	Neuronal Expression of the ERM-like Protein MIR in Rat Brain and Its Localization to Human Chromosome 6. Biochemical and Biophysical Research Communications, 2000, 279, 879-883.	2.1	18
66	Altered synaptic clustering of GABA_A receptors in mice lacking dystrophin (mdx mice). European Journal of Neuroscience, 1999, 11, 4457-4462.	2.6	211